PMC:7463108 / 761-1309 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T63421","span":{"begin":43,"end":46},"obj":"Body_part"},{"id":"T26171","span":{"begin":76,"end":79},"obj":"Body_part"},{"id":"T51689","span":{"begin":92,"end":96},"obj":"Body_part"},{"id":"T88958","span":{"begin":288,"end":291},"obj":"Body_part"},{"id":"T13436","span":{"begin":478,"end":481},"obj":"Body_part"}],"attributes":[{"id":"A12111","pred":"fma_id","subj":"T63421","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A43353","pred":"fma_id","subj":"T26171","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A88272","pred":"fma_id","subj":"T51689","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A51720","pred":"fma_id","subj":"T88958","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A75795","pred":"fma_id","subj":"T13436","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"anisms underlying opioid interactions with HIV, with emphasis on individual HIV-1-expressed gene products at the molecular, cellular and systems levels. Furthermore, we review preclinical and clinical studies with a focus on key considerations when addressing questions of whether opioid-HIV interactive pathogenesis results in unique structural or functional deficits not seen with either disease alone. These considerations include, understanding the combined consequences of HIV-1 genetic variants, host variants, and μ-opioid receptor (MOR) and"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T57883","span":{"begin":92,"end":96},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T35359","span":{"begin":214,"end":215},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T81874","span":{"begin":216,"end":221},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"anisms underlying opioid interactions with HIV, with emphasis on individual HIV-1-expressed gene products at the molecular, cellular and systems levels. Furthermore, we review preclinical and clinical studies with a focus on key considerations when addressing questions of whether opioid-HIV interactive pathogenesis results in unique structural or functional deficits not seen with either disease alone. These considerations include, understanding the combined consequences of HIV-1 genetic variants, host variants, and μ-opioid receptor (MOR) and"}

{"project":"LitCovid-PubTator","denotations":[{"id":"11","span":{"begin":521,"end":538},"obj":"Gene"},{"id":"12","span":{"begin":540,"end":543},"obj":"Gene"},{"id":"14","span":{"begin":76,"end":81},"obj":"Species"},{"id":"15","span":{"begin":478,"end":483},"obj":"Species"},{"id":"18","span":{"begin":43,"end":46},"obj":"Species"},{"id":"19","span":{"begin":288,"end":291},"obj":"Species"}],"attributes":[{"id":"A11","pred":"tao:has_database_id","subj":"11","obj":"Gene:4988"},{"id":"A12","pred":"tao:has_database_id","subj":"12","obj":"Gene:4988"},{"id":"A14","pred":"tao:has_database_id","subj":"14","obj":"Tax:11676"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"Tax:11676"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"Tax:12721"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Tax:12721"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"anisms underlying opioid interactions with HIV, with emphasis on individual HIV-1-expressed gene products at the molecular, cellular and systems levels. Furthermore, we review preclinical and clinical studies with a focus on key considerations when addressing questions of whether opioid-HIV interactive pathogenesis results in unique structural or functional deficits not seen with either disease alone. These considerations include, understanding the combined consequences of HIV-1 genetic variants, host variants, and μ-opioid receptor (MOR) and"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T96803","span":{"begin":304,"end":316},"obj":"http://purl.obolibrary.org/obo/GO_0009405"}],"text":"anisms underlying opioid interactions with HIV, with emphasis on individual HIV-1-expressed gene products at the molecular, cellular and systems levels. Furthermore, we review preclinical and clinical studies with a focus on key considerations when addressing questions of whether opioid-HIV interactive pathogenesis results in unique structural or functional deficits not seen with either disease alone. These considerations include, understanding the combined consequences of HIV-1 genetic variants, host variants, and μ-opioid receptor (MOR) and"}

{"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":153,"end":404},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"anisms underlying opioid interactions with HIV, with emphasis on individual HIV-1-expressed gene products at the molecular, cellular and systems levels. Furthermore, we review preclinical and clinical studies with a focus on key considerations when addressing questions of whether opioid-HIV interactive pathogenesis results in unique structural or functional deficits not seen with either disease alone. These considerations include, understanding the combined consequences of HIV-1 genetic variants, host variants, and μ-opioid receptor (MOR) and"}